Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
Aytu BioPharma
|
| gptkbp:acquisitionYear |
2021
|
| gptkbp:focusesOn |
gptkb:attention_deficit_hyperactivity_disorder
central nervous system disorders |
| gptkbp:foundedYear |
2009
|
| gptkbp:founder |
Vipin K. Garg
|
| gptkbp:headquartersLocation |
gptkb:Grand_Prairie,_Texas,_United_States
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:product |
gptkb:Adzenys_XR-ODT
Adzenys ER Cotempla XR-ODT generic Tussionex |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:NEOS
|
| gptkbp:bfsParent |
gptkb:Adzenys_XR-ODT
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Neos Therapeutics
|